ACH-000143

Research use only, not for human use.

ACH-000143 have been identified as a novel agonist of the melatonin receptors MT1 and MT2.

ACH-000143 have been identified as a novel agonist of the melatonin receptors MT1 and MT2.

——

ACH-000143 reduces liver triglycerides and steatosis in diet-Induced obese rats.ACH-000143 is devoid of hERG binding, genotoxicity, and behavioral alterations at doses up to 100 mg/kg p.o., supporting further investigation of this compound as a drug candidate.ACH-000143 significantly reduces plasma glucose at 10 mg/kg (?16.4%, p < 0.05) and 30 mg/kg (?16.9%, p < 0.01). Animal Model:High-fat diet rats.Dosage:10 and 30 mg/kg.Administration:Orally, once daily for two months.Result:Significantly reduced the weekly BW gain on weeks.

——

Others

Other Targets

MT1 receptor|MT2 receptor

——

——

2225836-30-4

297.74

C13H16ClN3O3

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (167.93 mM)

CC(NCCN1C2=CC(OC)=C(Cl)C=C2N=C1OC)=O

——

(-20℃)

With Ice Pack

≥ 2 years